Exhibit 99.2

ASX/NASDAQ Announcement

11 November 2025

2025 Annual General Meeting Results

In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 Immuron Limited (ASX: IMC; NASDAQ: IMRN or the Company) advises that the shareholders of the Company passed all resolutions in the Notice of Meeting at the 2025 Annual General Meeting held earlier today.

All resolutions put to the meeting were carried by way of a poll. All resolutions were carried. Details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

- - - END - - -

This release has been authorised by the Directors of Immuron Limited.

Further information

Steven Lydeamore

Chief Executive Officer

steve@immuron.com

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

Immuron Platform Technology

Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper- immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.

For more information visit: https://www.immuron.com.au/ and https://www.travelan.com

FORWARD-LOOKING STATEMENTS:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

Disclosure of Proxy Votes Immuron Limited Annual General Meeting Tuesday, 11 November 2025 In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting. Automic GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814 Results Poll Results (if applicable) Proxy Votes OUTCOME ABSTAIN AGAINST FOR PROXY'S DISCRETION ABSTAIN AGAINST FOR Total Number of Proxy Votes exercisable by proxies validly appointed Decided by Show of Hands (S) or Poll (P) Resolution - 1,420,323 3,938,845 21.51% 14,372,735 78.49% 186,971 1.02% 1,420,323 3,938,845 21.51% 14,185,764 77.47% 18,311,580 P 1 Adoption of Remuneration Report Carried 350,380 1,495,178 7.20% 19,256,845 92.80% 166,971 0.80% 350,380 1,495,178 7.20% 19,089,874 91.99% 20,752,023 P 2 Re - election of Director - Prof Ravi Savarirayan Carried 339,840 3,390,418 16.33% 17,372,145 83.67% 166,971 0.80% 339,840 3,390,418 16.33% 17,205,174 82.87% 20,762,563 P 3 Re - election of Director - Mr Paul Brennan Carried 33,240 1,925,198 9.14% 19,143,965 90.86% 316,971 1.50% 33,240 1,925,198 9.14% 18,826,994 89.36% 21,069,163 P 4 Approval of increased placement capacity Carried 148,640 4,075,508 19.45% 16,878,255 80.55% 186,971 0.89% 148,640 4,075,508 19.45% 16,691,284 79.66% 20,953,763 P 5 Approval of the Issue of Options to Dr Jeannette Joughin Carried 988,640 3,089,588 15.81% 16,455,425 84.19% 186,971 0.96% 988,640 3,089,588 15.81% 16,268,454 83.24% 19,545,013 P 6 Approval of the Issue of Options to Mr Daniel Pollock Carried 148,640 4,080,788 19.92% 16,404,225 80.08% 186,971 0.91% 148,640 4,080,788 19.92% 16,217,254 79.17% 20,485,013 P 7 Approval of the Issue of Options to Prof Ravi Savarirayan Carried 148,640 3,887,095 18.55% 17,066,668 81.45% 186,971 0.89% 148,640 3,887,095 18.55% 16,879,697 80.56% 20,953,763 P 8 Approval of the Issue of Options to Mr Paul Brennan

Results Poll Results (if applicable) Proxy Votes OUTCOME ABSTAIN AGAINST FOR PROXY'S DISCRETION ABSTAIN AGAINST FOR Total Number of Proxy Votes exercisable by proxies validly appointed Decided by Show of Hands (S) or Poll (P) Resolution Carried 230,240 1,689,334 8.09% 19,182,829 91.91% 316,971 1.52% 230,240 1,689,334 8.09% 18,865,858 90.39% 20,872,163 P 9 Ratification of prior issue of shares – Listing Rule 7.1 Carried 378,240 1,709,934 8.25% 19,014,229 91.75% 316,971 1.53% 378,240 1,709,934 8.25% 18,697,258 90.22% 20,724,163 P 10 Ratification of prior issue of shares – Listing Rule 7.1A Carried 19,797 2,092,978 9.93% 18,989,628 90.07% 192,494 0.91% 19,797 2,092,978 9.93% 18,797,134 89.16% 21,082,606 P 11 Approval to renew Proportional Takeover Bid